Rapid Response of Biologic Treatments of Moderate-to-Severe Plaque Psoriasis: A Comprehensive Investigation Using Bayesian and Frequentist Network Meta-analyses
Sign Up to like & getrecommendations! Published in 2019 at "Dermatology and Therapy"
DOI: 10.1007/s13555-019-00337-y
Abstract: Introduction Rapid improvement of psoriasis is valued by patients and should be considered to be an important factor in treatment selection. We investigated Psoriasis Area and Severity Index (PASI) and Dermatology Life Quality Index (DLQI)… read more here.
Keywords: rapid response; dermatology; psoriasis; moderate severe ... See more keywords
Is Clear Always Clear? Comparison of Psoriasis Area and Severity Index (PASI) and the Physician’s Global Assessment (PGA) in Psoriasis Clearance
Sign Up to like & getrecommendations! Published in 2020 at "Dermatology and Therapy"
DOI: 10.1007/s13555-020-00435-2
Abstract: Psoriasis Area and Severity Index (PASI) and Physician’s Global Assessment (PGA) are the most widely used outcome measures in clinical trials of biologics to treat psoriasis; however, these outcome measures vary in both their reliability… read more here.
Keywords: severity; pga; clearance; psoriasis ... See more keywords
Severity of Psoriasis Differs Between Men and Women: A Study of the Clinical Outcome Measure Psoriasis Area and Severity Index (PASI) in 5438 Swedish Register Patients
Sign Up to like & getrecommendations! Published in 2017 at "American Journal of Clinical Dermatology"
DOI: 10.1007/s40257-017-0274-0
Abstract: BackgroundPsoriasis is a common skin disease and moderate to severe psoriasis is associated with a dose-dependent risk for metabolic and cardiovascular morbidity. It has previously been speculated that women have less severe psoriasis, as men… read more here.
Keywords: area; severity; severe psoriasis; psoriasis ... See more keywords
Number needed to treat and costs per responder among biologic treatments for moderate-to-severe psoriasis: a network meta-analysis
Sign Up to like & getrecommendations! Published in 2018 at "Current Medical Research and Opinion"
DOI: 10.1080/03007995.2018.1457516
Abstract: Abstract Background: The clinical benefits of biologic therapies for moderate-to-severe psoriasis are well established, but wide variations exist in patient response. Objectives: To determine the number needed to treat (NNT) to achieve a 75% and… read more here.
Keywords: pasi; severe psoriasis; cost; moderate severe ... See more keywords
Absolute and relative psoriasis area and severity index (PASI) treatment goals and their association with health-related quality of life
Sign Up to like & getrecommendations! Published in 2020 at "Journal of Dermatological Treatment"
DOI: 10.1080/09546634.2020.1746734
Abstract: Abstract Background: Relative Psoriasis Area and Severity Index (PASI) improvement, also called ‘PASI response’, is recommended in major guidelines for assessment of treatment response in psoriasis patients. However, under certain circumstances it has some limitations,… read more here.
Keywords: index; response; absolute pasi; treatment ... See more keywords
Disease activity and treatment efficacy using patient-level Psoriasis Area and Severity Index scores from tildrakizumab phase 3 clinical trials
Sign Up to like & getrecommendations! Published in 2020 at "Journal of Dermatological Treatment"
DOI: 10.1080/09546634.2020.1747590
Abstract: Abstract Background It is unclear whether primary efficacy outcomes in plaque psoriasis clinical trials represent residual disease during treatment. Objectives To evaluate supplementing dichotomous efficacy with residual disease activity. Methods This post hoc analysis used… read more here.
Keywords: pasi; psoriasis; clinical trials; treatment ... See more keywords
Ustekinumab to guselkumab transitions: A series of 54 patients emulating the navigate trial in real life
Sign Up to like & getrecommendations! Published in 2022 at "Dermatologic Therapy"
DOI: 10.1111/dth.15757
Abstract: NAVIGATE clinical trial demonstrated a higher rate of Psoriasis Assesment Severity Index (PASI)90 response in patients treated with guselkumab when compared to ustekinumab and an improved response in those who switched from ustekinumab to guselkumab… read more here.
Keywords: ustekinumab guselkumab; trial; pasi; dosage regime ... See more keywords
AB0955 Tildrakizumab efficacy over time by week 28 response levels in two phase 3 clinical trials in patients with chronic plaque psoriasis
Sign Up to like & getrecommendations! Published in 2018 at "Annals of the Rheumatic Diseases"
DOI: 10.1136/annrheumdis-2018-eular.2983
Abstract: Background Tildrakizumab (TIL), a high affinity, humanised, IgG1/κ monoclonal antibody for IL-23p19, recently demonstrated efficacy in patients with chronic plaque psoriasis in two, phase 3 clinical trials. Objectives To examine efficacy from baseline to week… read more here.
Keywords: week; pfizer; celgene; pasi pasi ... See more keywords
Efficacy of Systemic Biologic Drugs in Pediatric Psoriasis: Evidence From Five Selected Randomized Clinical Trials
Sign Up to like & getrecommendations! Published in 2022 at "Frontiers in Pharmacology"
DOI: 10.3389/fphar.2022.847308
Abstract: Background: Psoriasis is a chronic, immune-mediated skin disease that may occur at any age. Prevalence in children ranges between 0.5 and 1.0% across Europe. Approximately 10–20% of paediatric psoriasis patients are moderate-to-severe in severity and… read more here.
Keywords: moderate severe; efficacy; pasi; psoriasis ... See more keywords
The social value of a PASI 90 or PASI 100 response in patients with moderate-to-severe plaque psoriasis in Spain
Sign Up to like & getrecommendations! Published in 2023 at "Frontiers in Public Health"
DOI: 10.3389/fpubh.2023.1000776
Abstract: Introduction Psoriasis is a chronic disease involving the skin, which significantly impacts the quality of life. Disease severity and treatment efficacy (i.e., response) are assessed through the Psoriasis Area and Severity Index (PASI). A PASI… read more here.
Keywords: pasi pasi; pasi response; pasi; pasi 100 ... See more keywords
A Real-Life Study on the Use of Tildrakizumab in Psoriatic Patients
Sign Up to like & getrecommendations! Published in 2023 at "Pharmaceuticals"
DOI: 10.3390/ph16040526
Abstract: Tildrakizumab is a humanized IgG1κ monoclonal antibody that selectively targets the p19 subunit of interleukin IL-23, thereby inhibiting the IL-23/IL-17 axis, which is primarily implicated in the immunopathogenesis of psoriasis. Tildrakizumab is approved for the… read more here.
Keywords: real life; psoriatic patients; life; pasi ... See more keywords